The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Updates in the AML field at ASH 2020
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some of the highlights he is looking forward to at ASH 2020 in the acute myeloid leukemia (AML) field. This includes updated results looking at venetoclax-combination therapy in various AML subgroups such as TP53-mutated and FLT3-mutated patients. There will also be lots of data focusing on immunotherapy, including novel antibody-drug conjugates and promising bispecific antibodies such as flotetuzumab, and promising initial data looking at menin inhibitors in MLL-rearranged AML. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
